{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:11:23Z","timestamp":1791465083420,"version":"4.3.4"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000092","name":"U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine","doi-asserted-by":"publisher","award":["T15LM0112750"],"award-info":[{"award-number":["T15LM0112750"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Systems biology perspectives are crucial for understanding the pathophysiology of complex diseases, and therefore hold great promise for the discovery of novel treatment strategies. Drug combinations have been shown to improve durability and reduce resistance to available first-line therapies in a variety of cancers; however, traditional drug discovery approaches are prohibitively cost and labor-intensive to evaluate large-scale matrices of potential drug combinations. Computational methods are needed to efficiently model complex interactions of drug target pathways and identify mechanisms underlying drug combination synergy. In this study, we employ a computational approach, SynGeNet (Synergy from Gene expression and Network mining), which integrates transcriptomics-based connectivity mapping and network centrality analysis to analyze disease networks and predict drug combinations. As an exemplar of a disease in which combination therapies demonstrate efficacy in genomic-specific contexts, we investigate malignant melanoma. We employed SynGeNet to generate drug combination predictions for each of the four major genomic subtypes of melanoma (BRAF, NRAS, NF1, and triple wild type) using publicly available gene expression and mutation data. We validated synergistic drug combinations predicted by our method across all genomic subtypes using results from a high-throughput drug screening study across. Finally, we prospectively validated the drug combination for\n                    <jats:italic>BRAF<\/jats:italic>\n                    -mutant melanoma that was top ranked by our approach, vemurafenib (BRAF inhibitor)\u2009+\u2009tretinoin (retinoic acid receptor agonist), using both in vitro and in vivo models of\n                    <jats:italic>BRAF<\/jats:italic>\n                    -mutant melanoma and RNA-sequencing analysis of drug-treated melanoma cells to validate the predicted mechanisms. Our approach is applicable to a wide range of disease domains, and, importantly, can model disease-relevant protein subnetworks in precision medicine contexts.\n                  <\/jats:p>","DOI":"10.1038\/s41540-019-0085-4","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T06:49:58Z","timestamp":1551163798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes"],"prefix":"10.1038","volume":"5","author":[{"given":"Kelly E.","family":"Regan-Fendt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"DiVincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan C.","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Shakya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryejung","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R. O.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"85_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13321-015-0055-9","volume":"7","author":"KA Ryall","year":"2015","unstructured":"Ryall, K. A. & Tan, A. C. Systems biology approaches for advancing the discovery of effective drug combinations. J. Cheminform. 7, 7 (2015).","journal-title":"J. Cheminform."},{"key":"85_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/clpt.2013.176","volume":"94","author":"JM Harrold","year":"2013","unstructured":"Harrold, J. M., Ramanathan, M. & Mager, D. E. Network-based approaches in drug discovery and early development. Clin. Pharmacol. Ther. 94, 651\u2013658 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"85_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/bib\/bbv020","volume":"17","author":"J Li","year":"2016","unstructured":"Li, J. et al. A survey of current trends in computational drug repositioning. Brief Bioinform. 17, 2\u201312 (2016).","journal-title":"Brief Bioinform."},{"key":"85_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/clpt.2013.1","volume":"93","author":"MR Hurle","year":"2013","unstructured":"Hurle, M. R. et al. Computational drug repositioning: from data to therapeutics. Clin. Pharmacol. Ther. 93, 335\u2013341 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"85_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/wsbm.51","volume":"2","author":"JD Feala","year":"2010","unstructured":"Feala, J. D. et al. Systems approaches and algorithms for discovery of combinatorial therapies. Wiley Interdiscip. Rev. Syst. Biol. Med. 2, 181\u2013193 (2010).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"85_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (New York, N. Y.) 313, 1929\u20131935 (2006).","journal-title":"Science (New York, N. Y.)"},{"key":"85_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: l1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452.e1417 (2017).","journal-title":"Cell"},{"key":"85_CR8","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"85_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","volume":"18","author":"S Landreville","year":"2012","unstructured":"Landreville, S. et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin. Cancer Res. 18, 408\u2013416 (2012).","journal-title":"Clin. Cancer Res."},{"key":"85_CR10","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/2159-8290.CD-13-0183","volume":"3","author":"NS Jahchan","year":"2013","unstructured":"Jahchan, N. S. et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3, 1364\u20131377 (2013).","journal-title":"Cancer Discov."},{"key":"85_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","volume":"10","author":"G Wei","year":"2006","unstructured":"Wei, G. et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10, 331\u2013342 (2006).","journal-title":"Cancer Cell"},{"key":"85_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042573","volume":"7","author":"JH Lee","year":"2012","unstructured":"Lee, J. H. et al. CDA: combinatorial drug discovery using transcriptional response modules. PLoS ONE 7, e42573 (2012).","journal-title":"PLoS ONE"},{"key":"85_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1681\/ASN.2012060590","volume":"24","author":"Y Zhong","year":"2013","unstructured":"Zhong, Y. et al. Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase. J. Am. Soc. Nephrol. 24, 801\u2013811 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"85_CR14","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.4161\/auto.6.8.13551","volume":"6","author":"F Iorio","year":"2010","unstructured":"Iorio, F., Isacchi, A., di Bernardo, D. & Brunetti-Pierri, N. Identification of small molecules enhancing autophagic function from drug network analysis. Autophagy 6, 1204\u20131205 (2010).","journal-title":"Autophagy"},{"key":"85_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4258\/hir.2014.20.1.52","volume":"20","author":"K Cha","year":"2014","unstructured":"Cha, K., Kim, M. S., Oh, K., Shin, H. & Yi, G. S. Drug similarity search based on combined signatures in gene expression profiles. Healthc. Inform. Res. 20, 52\u201360 (2014).","journal-title":"Healthc. Inform. Res."},{"key":"85_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","volume":"12","author":"AL Barabasi","year":"2011","unstructured":"Barabasi, A. L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56\u201368 (2011).","journal-title":"Nat. Rev. Genet."},{"key":"85_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.drudis.2012.09.003","volume":"18","author":"BJ Schmidt","year":"2013","unstructured":"Schmidt, B. J., Papin, J. A. & Musante, C. J. Mechanistic systems modeling to guide drug discovery and development. Drug Discov. Today 18, 116\u2013127 (2013).","journal-title":"Drug Discov. Today"},{"key":"85_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002503","volume":"8","author":"F Cheng","year":"2012","unstructured":"Cheng, F. et al. Prediction of drug\u2013target interactions and drug repositioning via network-based inference. PLoS Comput. Biol. 8, e1002503 (2012).","journal-title":"PLoS Comput. Biol."},{"key":"85_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1752-0509-6-27","volume":"6","author":"AK Chavali","year":"2012","unstructured":"Chavali, A. K. et al. Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease. BMC Syst. Biol. 6, 27\u201327 (2012).","journal-title":"BMC Syst. Biol."},{"key":"85_CR20","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-5-S1-S11","volume":"5","author":"Z Li","year":"2011","unstructured":"Li, Z., Wang, R.-S. & Zhang, X.-S. Two-stage flux balance analysis of metabolic networks for drug target identification. BMC Syst. Biol. 5, S11\u2013S11 (2011).","journal-title":"BMC Syst. Biol."},{"key":"85_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrd2826","volume":"8","author":"EE Schadt","year":"2009","unstructured":"Schadt, E. E., Friend, S. H. & Shaywitz, D. A. A network view of disease and compound screening. Nat. Rev. Drug Discov. 8, 286\u2013295 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"85_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fgene.2014.00160","volume":"5","author":"JP Pinto","year":"2014","unstructured":"Pinto, J. P., Machado, R. S., Xavier, J. M. & Futschik, M. E. Targeting molecular networks for drug research. Front. Genet. 5, 160 (2014).","journal-title":"Front. Genet."},{"key":"85_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000938","volume":"6","author":"RL Chang","year":"2010","unstructured":"Chang, R. L., Xie, L., Xie, L., Bourne, P. E. & Palsson, B. \u00d8. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput. Biol. 6, e1000938 (2010).","journal-title":"PLoS Comput. Biol."},{"key":"85_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9481","volume":"6","author":"Y Sun","year":"2015","unstructured":"Sun, Y. et al. Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. Nat. Commun. 6, 8481 (2015).","journal-title":"Nat. Commun."},{"key":"85_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-015-0202-y","volume":"9","author":"D Chen","year":"2015","unstructured":"Chen, D., Liu, X., Yang, Y., Yang, H. & Lu, P. Systematic synergy modeling: understanding drug synergy from a systems biology perspective. BMC Syst. Biol. 9, 56 (2015).","journal-title":"BMC Syst. Biol."},{"key":"85_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.29","volume":"4","author":"AS Brown","year":"2017","unstructured":"Brown, A. S. & Patel, C. J. A standard database for drug repositioning. Sci. Data 4, 170029 (2017).","journal-title":"Sci. Data"},{"key":"85_CR27","unstructured":"Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681\u20131696 (2015). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26091043."},{"key":"85_CR28","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"Shain, A. H. et al. The genetic evolution of melanoma from precursor lesions. N. Engl. J. Med. 373, 1926\u20131936 (2015).","journal-title":"N. Engl. J. Med."},{"key":"85_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1586\/era.11.30","volume":"11","author":"JK John","year":"2011","unstructured":"John, J. K. & Smalley, K. S. Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis? Expert Rev. Anticancer Ther. 11, 711\u2013714 (2011).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"85_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1393","volume":"43","author":"D Bertrand","year":"2015","unstructured":"Bertrand, D. et al. Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles. Nucleic Acids Res. 43, e44 (2015).","journal-title":"Nucleic Acids Res."},{"key":"85_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygeno.2016.04.005","volume":"107","author":"Y Jiang","year":"2016","unstructured":"Jiang, Y. et al. Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics 107, 223\u2013230 (2016).","journal-title":"Genomics"},{"key":"85_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep07857","volume":"5","author":"J Guan","year":"2015","unstructured":"Guan, J., Gupta, R. & Filipp, F. V. Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. Sci. Rep. 5, 7857 (2015).","journal-title":"Sci. Rep."},{"key":"85_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11864-016-0436-y","volume":"17","author":"M Polkowska","year":"2016","unstructured":"Polkowska, M., Czepielewska, E. & Kozlowska-Wojciechowska, M. Drug combinations as the new standard for melanoma treatment. Curr. Treat. Option. Oncol. 17, 61 (2016).","journal-title":"Curr. Treat. Option. Oncol."},{"key":"85_CR34","first-page":"247","volume":"2017","author":"KE Regan","year":"2017","unstructured":"Regan, K. E., Payne, P. R. O. & Li, F. Integrative network and transcriptomics-based approach predicts genotype-specific drug combinations for melanoma. AMIA Jt. Summits Transl. Sci. Proc. 2017, 247\u2013256 (2017).","journal-title":"AMIA Jt. Summits Transl. Sci. Proc."},{"key":"85_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140310","volume":"10","author":"AA Friedman","year":"2015","unstructured":"Friedman, A. A. et al. Landscape of targeted anti-cancer drug synergies in melanoma identifies a novel BRAF-VEGFR\/PDGFR combination treatment. PLoS ONE 10, e0140310 (2015).","journal-title":"PLoS ONE"},{"key":"85_CR36","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1073\/pnas.1004751108","volume":"108","author":"M Bailly-Bechet","year":"2011","unstructured":"Bailly-Bechet, M. et al. Finding undetected protein associations in cell signaling by belief propagation. Proc. Natl. Acad. Sci. USA 108, 882\u2013887 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"85_CR37","first-page":"3183","volume":"55","author":"DR Shalinsky","year":"1995","unstructured":"Shalinsky, D. R. et al. Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice. Cancer Res. 55, 3183\u20133191 (1995).","journal-title":"Cancer Res."},{"key":"85_CR38","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1124\/jpet.107.131045","volume":"324","author":"T Wang","year":"2008","unstructured":"Wang, T., Ma, X., Krausz, K. W., Idle, J. R. & Gonzalez, F. J. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J. Pharmacol. Exp. Ther. 324, 674\u2013684 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"85_CR39","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1073\/pnas.1222863110","volume":"110","author":"B Jiao","year":"2013","unstructured":"Jiao, B. et al. 8-CPT-cAMP\/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF\/RARalpha degradation. Proc. Natl. Acad. Sci. USA 110, 3495\u20133500 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"85_CR40","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1704371114","volume":"114","author":"MC Duggan","year":"2017","unstructured":"Duggan, M. C. et al. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. Proc. Natl. Acad. Sci. USA 114, 9629\u20139634 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"85_CR41","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/jid.2014.18","volume":"134","author":"AL Donato","year":"2014","unstructured":"Donato, A. L. et al. Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy. J. Invest. Dermatol. 134, 1686\u20131692 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"85_CR42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/CMR.0b013e32835f28d8","volume":"23","author":"YR Liu","year":"2013","unstructured":"Liu, Y. R. et al. Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Res. 23, 243\u2013253 (2013).","journal-title":"Melanoma Res."},{"key":"85_CR43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.molonc.2013.11.005","volume":"8","author":"H Escuin-Ordinas","year":"2014","unstructured":"Escuin-Ordinas, H. et al. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol. Oncol. 8, 250\u2013260 (2014).","journal-title":"Mol. Oncol."},{"key":"85_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","volume":"3","author":"MR Girotti","year":"2013","unstructured":"Girotti, M. R. et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158\u2013167 (2013).","journal-title":"Cancer Discov."},{"key":"85_CR45","doi-asserted-by":"publisher","first-page":"89182","DOI":"10.18632\/oncotarget.21269","volume":"8","author":"Y Zakharia","year":"2017","unstructured":"Zakharia, Y. et al. Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: a phase lb study. Oncotarget 8, 89182\u201389193 (2017).","journal-title":"Oncotarget"},{"key":"85_CR46","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/jcb.21530","volume":"102","author":"AL Fields","year":"2007","unstructured":"Fields, A. L., Soprano, D. R. & Soprano, K. J. Retinoids in biological control and cancer. J. Cell. Biochem. 102, 886\u2013898 (2007).","journal-title":"J. Cell. Biochem."},{"key":"85_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3109\/07357907.2014.964408","volume":"32","author":"Siddikuzzaman","year":"2014","unstructured":"Siddikuzzaman & Grace, V. M. Anti-metastatic study of liposome-encapsulated all trans retinoic acid (ATRA) in B16F10 melanoma cells-implanted C57BL\/6 mice. Cancer Invest. 32, 507\u2013517 (2014).","journal-title":"Cancer Invest."},{"key":"85_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/14656566.3.3.299","volume":"3","author":"RM Niles","year":"2002","unstructured":"Niles, R. M. The use of retinoids in the prevention and treatment of skin cancer. Expert Opin. Pharmacother. 3, 299\u2013303 (2002).","journal-title":"Expert Opin. Pharmacother."},{"key":"85_CR49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/imm.12768","volume":"152","author":"W Yin","year":"2017","unstructured":"Yin, W., Song, Y., Liu, Q., Wu, Y. & He, R. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8(+) T-cell immunity. Immunology 152, 287\u2013297 (2017).","journal-title":"Immunology"},{"key":"85_CR50","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/jid.2012.21","volume":"132","author":"MM Asgari","year":"2012","unstructured":"Asgari, M. M., Brasky, T. M. & White, E. Association of vitamin A and carotenoid intake with melanoma risk in a large prospective cohort. J. Invest. Dermatol. 132, 1573\u20131582 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"85_CR51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/annonc\/mdw660","volume":"28","author":"M Bolis","year":"2017","unstructured":"Bolis, M. et al. Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid. Ann. Oncol. 28, 611\u2013621 (2017).","journal-title":"Ann. Oncol."},{"key":"85_CR52","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-06-3026","volume":"13","author":"N Chakravarti","year":"2007","unstructured":"Chakravarti, N. et al. Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin. Cancer Res. 13, 4817\u20134824 (2007).","journal-title":"Clin. Cancer Res."},{"key":"85_CR53","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3892\/or.2016.5048","volume":"36","author":"J Zhao","year":"2016","unstructured":"Zhao, J., Zeng, X., Song, P., Wu, X. & Shi, H. AKT1 as the PageRank hub gene is associated with melanoma and its functional annotation is highly related to the estrogen signaling pathway that may regulate the growth of melanoma. Oncol. Rep. 36, 2087\u20132093 (2016).","journal-title":"Oncol. Rep."},{"key":"85_CR54","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.celrep.2015.09.057","volume":"13","author":"JH Cho","year":"2015","unstructured":"Cho, J. H. et al. AKT1 activation promotes development of melanoma metastases. Cell Rep. 13, 898\u2013905 (2015).","journal-title":"Cell Rep."},{"key":"85_CR55","doi-asserted-by":"publisher","first-page":"30525","DOI":"10.1074\/jbc.M114.593210","volume":"289","author":"HY Kwan","year":"2014","unstructured":"Kwan, H. Y. et al. Subcutaneous adipocytes promote melanoma cell growth by activating the Akt signaling pathway: role of palmitic acid. J. Biol. Chem. 289, 30525\u201330537 (2014).","journal-title":"J. Biol. Chem."},{"key":"85_CR56","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1200\/JCO.2005.07.168","volume":"23","author":"DL Dai","year":"2005","unstructured":"Dai, D. L., Martinka, M. & Li, G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23, 1473\u20131482 (2005).","journal-title":"J. Clin. Oncol."},{"key":"85_CR57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/CMR.0000000000000368","volume":"27","author":"CD Soares","year":"2017","unstructured":"Soares, C. D. et al. Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas. Melanoma Res. 27, 448\u2013456 (2017).","journal-title":"Melanoma Res."},{"key":"85_CR58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/2159-8290.CD-13-0279","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi, H. et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 4, 69\u201379 (2014).","journal-title":"Cancer Discov."},{"key":"85_CR59","doi-asserted-by":"publisher","first-page":"E536","DOI":"10.1073\/pnas.1418163112","volume":"112","author":"D Perna","year":"2015","unstructured":"Perna, D. et al. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc. Natl. Acad. Sci. USA 112, E536\u2013E545 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"85_CR60","doi-asserted-by":"crossref","first-page":"17771","DOI":"10.18632\/oncotarget.14849","volume":"8","author":"G Song","year":"2017","unstructured":"Song, G. et al. SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB. Oncotarget 8, 17771\u201317784 (2017).","journal-title":"Oncotarget"},{"key":"85_CR61","first-page":"4502","volume":"9","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. High expression of fibronectin 1 suppresses apoptosis through the NF-kappaB pathway and is associated with migration in nasopharyngeal carcinoma. Am. J. Transl. Res. 9, 4502\u20134511 (2017).","journal-title":"Am. J. Transl. Res."},{"key":"85_CR62","first-page":"7880","volume":"14","author":"J Wang","year":"2017","unstructured":"Wang, J., Du, Q. & Li, C. Bioinformatics analysis of gene expression profiles to identify causal genes in luminal B2 breast cancer. Oncol. Lett. 14, 7880\u20137888 (2017).","journal-title":"Oncol. Lett."},{"key":"85_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09691-3","volume":"7","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Serum fibronectin distinguishes the early stages of hepatocellular carcinoma. Sci. Rep. 7, 9449 (2017).","journal-title":"Sci. Rep."},{"key":"85_CR64","doi-asserted-by":"publisher","unstructured":"Cai, X. et al. Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration and invasion. J. Cell. Biochem. https:\/\/doi.org\/10.1002\/jcb.26651 (2017).","DOI":"10.1002\/jcb.26651"},{"key":"85_CR65","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1158\/0008-5472.CAN-05-2367","volume":"66","author":"S Han","year":"2006","unstructured":"Han, S., Khuri, F. R. & Roman, J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt\/mammalian target of rapamycin\/S6 kinase and inactivation of LKB1\/AMP-activated protein kinase signal pathways. Cancer Res. 66, 315\u2013323 (2006).","journal-title":"Cancer Res."},{"key":"85_CR66","first-page":"7799","volume":"14","author":"Y Ye","year":"2017","unstructured":"Ye, Y. et al. MicroRNA-139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression. Oncol. Lett. 14, 7799\u20137806 (2017).","journal-title":"Oncol. Lett."},{"key":"85_CR67","first-page":"75","volume":"24","author":"X Yang","year":"2017","unstructured":"Yang, X. et al. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. Discov. Med. 24, 75\u201385 (2017).","journal-title":"Discov. Med."},{"key":"85_CR68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.biopha.2017.01.023","volume":"88","author":"H Zhang","year":"2017","unstructured":"Zhang, H., Sun, Z., Li, Y., Fan, D. & Jiang, H. MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells. Biomed. Pharmacother. 88, 285\u2013292 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"85_CR69","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/modpathol.2013.228","volume":"27","author":"J Wouters","year":"2014","unstructured":"Wouters, J. et al. A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value. Mod. Pathol. 27, 1088\u20131100 (2014).","journal-title":"Mod. Pathol."},{"key":"85_CR70","first-page":"16","volume":"28","author":"TW Valente","year":"2008","unstructured":"Valente, T. W., Coronges, K., Lakon, C. & Costenbader, E. How correlated are network centrality measures? Connect (Tor., Ont.) 28, 16\u201326 (2008).","journal-title":"Connect (Tor., Ont.)"},{"key":"85_CR71","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/ng.3382","volume":"47","author":"AH Shain","year":"2015","unstructured":"Shain, A. H. et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat. Genet. 47, 1194\u20131199 (2015).","journal-title":"Nat. Genet."},{"key":"85_CR72","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/pcmr.12459","volume":"29","author":"T Zhang","year":"2016","unstructured":"Zhang, T., Dutton-Regester, K., Brown, K. M. & Hayward, N. K. The genomic landscape of cutaneous melanoma. Pigment Cell Melanoma Res. 29, 266\u2013283 (2016).","journal-title":"Pigment Cell Melanoma Res."},{"key":"85_CR73","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1158\/1078-0432.CCR-12-3140","volume":"19","author":"A Spreafico","year":"2013","unstructured":"Spreafico, A. et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt\/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin. Cancer Res. 19, 4149\u20134162 (2013).","journal-title":"Clin. Cancer Res."},{"key":"85_CR74","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1200\/JCO.2017.35.15_suppl.2587","volume":"35","author":"A Krishnamurthy","year":"2017","unstructured":"Krishnamurthy, A. et al. A phase IB study of the combination of selumetinib (AZD6244, ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). J. Clin. Oncol. 35, 2587\u20132587 (2017).","journal-title":"J. Clin. Oncol."},{"key":"85_CR75","unstructured":"Cheng, J. et al. Evaluation of analytical methods for connectivity map data. Pacific Symp. Biocomput. 5\u201316 (2013)."},{"key":"85_CR76","doi-asserted-by":"publisher","first-page":"E3725","DOI":"10.1073\/pnas.1520289113","volume":"113","author":"B Malcomson","year":"2016","unstructured":"Malcomson, B. et al. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis. Proc. Natl. Acad. Sci. USA 113, E3725\u2013E3734 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"85_CR77","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nbt.3052","volume":"32","author":"M Bansal","year":"2014","unstructured":"Bansal, M. et al. A community computational challenge to predict the activity of pairs of compounds. Nat. Biotechnol. 32, 1213\u20131222 (2014).","journal-title":"Nat. Biotechnol."},{"key":"85_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-016-0326-8","volume":"10","author":"NB Torres","year":"2016","unstructured":"Torres, N. B. & Altafini, C. Drug combinatorics and side effect estimation on the signed human drug-target network. BMC Syst. Biol. 10, 74 (2016).","journal-title":"BMC Syst. Biol."},{"key":"85_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/srep07160","volume":"4","author":"H Huang","year":"2014","unstructured":"Huang, H., Zhang, P., Qu, X. A., Sanseau, P. & Yang, L. Systematic prediction of drug combinations based on clinical side-effects. Sci. Rep. 4, 7160 (2014).","journal-title":"Sci. Rep."},{"key":"85_CR80","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/bioinformatics\/btw168","volume":"32","author":"Z Wang","year":"2016","unstructured":"Wang, Z., Clark, N. R. & Ma\u2019ayan, A. Drug-induced adverse events prediction with the LINCS L1000 data. Bioinformatics (Oxf., Engl.) 32, 2338\u20132345 (2016).","journal-title":"Bioinformatics (Oxf., Engl.)"},{"key":"85_CR81","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nbt.3367","volume":"34","author":"BA Kidd","year":"2016","unstructured":"Kidd, B. A. et al. Mapping the effects of drugs on the immune system. Nat. Biotechnol. 34, 47\u201354 (2016).","journal-title":"Nat. Biotechnol."},{"key":"85_CR82","doi-asserted-by":"publisher","first-page":"8270","DOI":"10.1158\/1078-0432.CCR-08-0165","volume":"14","author":"S Kusmartsev","year":"2008","unstructured":"Kusmartsev, S. et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14, 8270\u20138278 (2008).","journal-title":"Clin. Cancer Res."},{"key":"85_CR83","doi-asserted-by":"publisher","first-page":"D833","DOI":"10.1093\/nar\/gkw943","volume":"45","author":"J Pinero","year":"2017","unstructured":"Pinero, J. et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 45, D833\u2013d839 (2017).","journal-title":"Nucleic Acids Res."},{"key":"85_CR84","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"85_CR85","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"85_CR86","doi-asserted-by":"publisher","first-page":"D369","DOI":"10.1093\/nar\/gkw1102","volume":"45","author":"A Chatr-Aryamontri","year":"2017","unstructured":"Chatr-Aryamontri, A. et al. The BioGRID interaction database: 2017 update. Nucleic Acids Res. 45, D369\u2013d379 (2017).","journal-title":"Nucleic Acids Res."},{"key":"85_CR87","doi-asserted-by":"publisher","unstructured":"Koleti, A. et al. Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkx1063 (2017).","DOI":"10.1093\/nar\/gkx1063"},{"key":"85_CR88","doi-asserted-by":"publisher","unstructured":"Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkx1037 (2017).","DOI":"10.1093\/nar\/gkx1037"},{"key":"85_CR89","doi-asserted-by":"publisher","first-page":"D401","DOI":"10.1093\/nar\/gkt1207","volume":"42","author":"M Kuhn","year":"2014","unstructured":"Kuhn, M. et al. STITCH 4: integration of protein\u2013chemical interactions with user data. Nucleic Acids Res. 42, D401\u2013D407 (2014).","journal-title":"Nucleic Acids Res."},{"key":"85_CR90","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45, D353\u2013d361 (2017).","journal-title":"Nucleic Acids Res."},{"key":"85_CR91","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251\u2013263 (2012).","journal-title":"Cell"},{"key":"85_CR92","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/jid.2013.197","volume":"133","author":"L Raskin","year":"2013","unstructured":"Raskin, L. et al. Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J. Invest. Dermatol. 133, 2585\u20132592 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"85_CR93","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-019-0085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-019-0085-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-019-0085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T22:06:28Z","timestamp":1671228388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-019-0085-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1038\/s41540-019-0085-4","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"23 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}